BLTE - Belite Bio, Inc Debt to Book Capitalization Ratio

Belite Bio, Inc (BLTE) develops ophthalmological drugs, leveraging partnerships with leading scientific centers to accelerate drug commercialization. The company's growth is based on Tinlarebant trials and the prospects of combating macular degeneration, with the metric standing at 0.00. This chart of the market price visualizes the asset's price action. Business stability is ensured by patent protection and minimal impact from global political conflicts.

BLTE (Belite Bio, Inc.) Debt to Book Value history from 04/28/2023 to 10/28/2026

Metric breakdowns and analytics for Belite Bio, Inc (BLTE)

- price and consensus price forecast:

Stock Price Belite Bio Corp|BLTE - Analyst Consensus Forecast

- market capitalization data:

Market Value Belite Bio Pharma|BLTE - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Belite Bio|BLTE - Company Net Assets|Market Capitalization to Book Value Ratio belitebio.com|BLTE - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Belite Bio, Inc|BLTE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital belitebio.com|BLTE - Company Cumulative Debt|Debt to Book Value Belite Bio Pharma

Analysis of all company metrics:Belite Bio, Inc. - BLTE

This ratio measures the degree of financial autonomy by comparing total liabilities to equity to assess the debt load. By analyzing the debt-to-book capitalization ratio of Belite Bio, Inc (BLTE) on GURU.Markets, an investor can track the solvency dynamics of Belite Bio, Inc (BLTE), which is critical when outsourcing production to third-party contractors (CRO/CMO) to minimize capital expenditures for drug development.

Competitors of Belite Bio, Inc